Skip to NavigationSkip to content

hydroxychloroquine

Lancet expresses concern over published hydroxychloroquine and chloroquine paper

Photo by Joegoauk Goa

The Lancet’s editors have expressed their concerns over a paper published in their journal that said hydroxychloroquine and chloroquine was dangerous for use in COVID-19 patients.

The paper was published on 22 May, and found the two drugs are linked to an increased risk of death and heart arrhythmias among people admitted to hospital with the virus. The authors of this study said neither should be used to treat the coronavirus outside of a clinical trial.

European countries reject hydroxychloroquine treatments for COVID-19

License to use Creative Commons Zero/Photo from PeakPix

Multiple European countries have rejected the use of hydroxychloroquine in patients suffering from coronavirus, due to a lack of evidence that it is effective.

On Tuesday, France’s public health agency advised against the use of hydroxychloroquine following a Lancet study published last week that casted doubt on the benefit of COVID-19 patients taking either the drug or chloroquine.

UK begins hydroxychloroquine trial

Photo by Kuldeep Singh

A trial investigating the effectiveness of hydroxychloroquine against COVID-19 has begun in the UK.

The first participants will be enrolled from today at the Brighton and Sussex University hospitals and the John Radcliffe Hospital in Oxford. They will be given either hydroxychloroquine or a placebo for three months. These are the first of 25 UK sites, with results expected to be collected by the end of the year.

Trump claims he is taking hydroxychloroquine to prevent contracting COVID-19

Photo by Gage Skidmore

President Donald Trump told reporters last night that he is taking the drug hydroxychloroquine to ward off COVID-19, despite US health officials warning the drug may be unsafe.

He told reporters: “You’d be surprised at how many people are taking it. The frontline workers many many are taking it. I happen to be taking it. I happen to be taking it. I’m taking it, hydroxychloroquine. Right now, yeah. A couple weeks ago I started taking it. Because I think it’s good, I heard a lot of good stories, I take a pill every day.”

Latest large hydroxychloroquine study suggests it does not help treat COVID-19

Photo Simon Davis/DFID

The results of another study into the use of hydroxychloroquine in COVID-19 patients has cast further doubts on its effectiveness in treating the virus.

Ousted chief of BARDA says Trump administration ignored COVID-19 warnings

Photo by Joyce N. Boghosian

Ousted Director of the Biomedical Advanced Research and Development Authority (BARDA), Dr Rick Bright, alleges the Trump administration ignored warnings about the severity of the coronavirus.

Much of his complaints, and what he believes led to him being ousted, was the administration pushing hydroxychloroquine and chloroquine as a coronavirus treatment.

Arizona GOP lawmakers and AAPS say hydroxychloroquine has 90% chance of helping COVID-19 patients, but data is not based on clinical trials

Photo by Governor Tom Wolf

The Association of American Physicians and Surgeons (AAPS) wrote a letter to Republican Arizona Governor Doug Ducey urging the wider use of hydroxychloroquine, based on data they have collected.

Pharmafile.com's weekly COVID-19 news round-up

Photo by CDC

Hydroxychloroquine continues to feature in coronavirus news. Rick Bright, the Director of BARDA, alleges he was pushed out of his position due to his pushback to the administration focusing on the use of hydroxychloroquine in COVID-19 patients. This came after the National Institutes of Health said coronavirus patients should not take the drug due to potential “toxicities.”

Researchers have also been investigating the heartburn drug Pepcid, as a potential treatment, while the FDA has granted emergency clearance for the first in-home testing kit.

FDA urges close monitoring of COVID-19 patients treated with hydroxychloroquine

Photo by Bicanski

The FDA has released a safety communication reiterating the need for doctors to closely monitor COVID-19 patients who are treated with either hydroxychloroquine or chloroquine.

This is due to severe side effects that have become apparent in multiple clinical trials in testing how effective the drug is in treating the coronavirus.

Pharmafile.com's weekly COVID-19 news round-up

Photo by CDC

Hydroxychloroquine has faced setbacks as a potential COVID-19 treatment, as it failed a clinical trial in France and a study in China found it did not speed up recovery from the coronavirus.

In other news, new research suggests that social distancing could be put in place until 2022 while the FDA is warning that the pandemic will slow down the review of drugs for approval.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches